Open Orphan #ORPH – Contract extension with Carna Biosciences

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with Carna Biosciences, Inc. (“Carna”), extending its integrated drug development consultancy services with Venn Life Sciences (“Venn”), part of Open Orphan plc. Carna […]

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its […]

Open Orphan #ORPH – New Contract Win with Carna Bioscience

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a new contract with Carna Bioscience ( www.carnabio.com ) for a First In Human Clinical pharmacology trial. The contract […]